"The Bio-Techne team once again executed at a high level and delivered strong second quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "It is encouraging to ...
StockStory.org on MSN
Research tools & consumables stocks Q3 results: Benchmarking Bio-Techne (NASDAQ:TECH)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...
Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
11d
Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return
Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...
In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...
Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...
MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
Bio-Techne (TECH) has delivered a -18.08% change over the past year, with a 52-week range between 46.01 and 79.28. What Is the Average Daily Trading Volume of Bio-Techne (TECH)? The average daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback